Nabriva Therapeutics AG (NASDAQ:NBRV) – Equities research analysts at Leerink Swann lifted their FY2017 EPS estimates for Nabriva Therapeutics AG in a research report issued to clients and investors on Monday. Leerink Swann analyst P. Matteis now expects that the biotechnology company will earn ($2.13) per share for the year, up from their previous estimate of ($2.16). Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock. Leerink Swann also issued estimates for Nabriva Therapeutics AG’s Q4 2017 earnings at ($0.47) EPS and FY2018 earnings at ($2.36) EPS.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.34 million.

TRADEMARK VIOLATION NOTICE: “Brokers Set Expectations for Nabriva Therapeutics AG’s FY2017 Earnings (NBRV)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/20/brokers-set-expectations-for-nabriva-therapeutics-ags-fy2017-earnings-nbrv.html.

A number of other research firms also recently issued reports on NBRV. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Nabriva Therapeutics AG in a research report on Tuesday. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Thursday, August 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research report on Monday. Wedbush reiterated an “outperform” rating and set a $21.00 price target (up from $13.00) on shares of Nabriva Therapeutics AG in a research report on Monday. Finally, ValuEngine downgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $19.13.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 9.19 on Wednesday. The stock’s market capitalization is $246.64 million. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $14.10. The firm’s 50-day moving average price is $9.01 and its 200 day moving average price is $10.19.

In related news, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average cost of $9.46 per share, for a total transaction of $497,889.26. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $10.94, for a total value of $143,609.38. Following the transaction, the insider now owns 2,583,229 shares of the company’s stock, valued at $28,260,525.26. The disclosure for this sale can be found here. Insiders have sold a total of 279,000 shares of company stock valued at $2,870,869 over the last 90 days. Insiders own 2.75% of the company’s stock.

Several institutional investors have recently modified their holdings of NBRV. Almanack Investment Partners LLC. raised its position in shares of Nabriva Therapeutics AG by 482.2% during the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after purchasing an additional 751,366 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Nabriva Therapeutics AG by 9.9% during the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after purchasing an additional 193,951 shares during the last quarter. Nationwide Fund Advisors acquired a new position in shares of Nabriva Therapeutics AG during the 1st quarter worth approximately $2,074,000. Finally, Royal Bank of Canada raised its position in shares of Nabriva Therapeutics AG by 19.6% during the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares during the last quarter. Hedge funds and other institutional investors own 68.56% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Earnings History and Estimates for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.